Cinda Biorecoa Whole Human Source Anti-CD47 monoclonal antibody body approved by FDA for drug clinical trial

recently, Cinda Bio announced that theCompany(developed recombinant whole-human source anti-CD47 monoclonal antibody (research code: IBI-188), has been the United States FoodDrug(theDrugissued by the Supervisory Authority (clinicaltest(approve, to carry out clinical research in patients with solid tumors and blood tumors)about IBI-188
IBI-188 is theof Sinda Bio
Pharmaceuticals (developed an independently valued anti-CD47 IgG4 monoclonal antibody intended to treat a wide range of blood and solid tumors, including non-Hodgkin's lymphoma and ovarian cancer)in vivo and external experiments have shown that IBI-188 can bind to the CD47 antigen on the surface of tumor cells, block the CD47-SIRP alpha signaling pathway, inhibit the CD47 transmission of the "don't eat me" signal, prompting macrophages to recognize the tumor cell transmission of the "eat me" signal, thereby devouring tumor cells, play the body's anti-tumor effectFrom preclinical data, IBI-188 has a stronger blocking capacity than similar drugsabout IBI-308 (Sindili mono-resistance)Sindilli monoantigen is an all-human cell procedural death-1 (Programmed Death Cell 1, PD-1) monoclonal antibody that binds to the PD-1 receptor on the surface of the T cell, blocks its binding with the ligand PD-L1, and makes T-cell and autoimmune play a normal role, and then destroy tumor cells Sindy Li monoantigen is a PD-1 monoclonal antibody developed by Cinda Bio and Lilly Pharmaceuticals in China the State Drug Administration has officially accepted the Sindy Li mono-anti-marketing application submitted by Cinda Bio on April 16, 2018, and on April 23, it was included in the priority review of the drug application for the first indication of recurrent/difficult to treat classic Hodgkin's lymphoma